PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
PTC Therapeutics (PTCT) Posts Smaller-than-Expected Q4 Loss
March 16, 2017 7:33 AM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($0.78), $0.29 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $25.2 million versus the consensus estimate of $24.04 million.
2017 Guidance:
For 2017, PTC expects to achieve ex-U.S. Translarna net sales between $105 and $125 million, assuming... More
